ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

FDBK Feedback Plc

97.50
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB00BJN59X09 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 97.50 95.00 100.00 97.50 97.50 97.50 5,188 07:36:53
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Electronic Computers 1.03M -2.92M -0.2188 -4.46 13M
Feedback Plc is listed in the Electronic Computers sector of the London Stock Exchange with ticker FDBK. The last closing price for Feedback was 97.50p. Over the last year, Feedback shares have traded in a share price range of 58.00p to 150.00p.

Feedback currently has 13,334,659 shares in issue. The market capitalisation of Feedback is £13 million. Feedback has a price to earnings ratio (PE ratio) of -4.46.

Feedback Share Discussion Threads

Showing 13051 to 13071 of 14800 messages
Chat Pages: Latest  532  531  530  529  528  527  526  525  524  523  522  521  Older
DateSubjectAuthorDiscuss
14/2/2022
17:09
LR2, I am well aware of the new financial year and I hope you are right and Bleepa does see some money thrown towards them.
I suppose one could look at that figure of 900 clinicians at Pennine who are now using Bleepa and view that as a huge positive and I do believe it is. Hat still waiting if we never see a contract coming through from them.
If the first CDC contract ever comes through, I will be doubling my multi million holding, so yes buyers are likely waiting for something like this first.

petekand
14/2/2022
15:10
Pete, the Pennine Acute Hospital Trust signed up for Bleepa rollout in April 2020 and the Royal Berkshire Foundation Trust in late March 2021. Why then? Why springtime? Because each and every NHS hospital has the same new financial year start date of April. In April of each year all NHS hospitals get their hands on a new cash lump sum to spend. So, that's why I believe there will plenty of news in March / April. News about hospitals, community diagnostic centres (9), and India of course.

If there isn't any NHS news in the next two months, then Bleepa has a problem with the NHS and will have to double down on its Indian leads of Orissa and Rajasthan. Incidentally, both states have roughly similar populations to the UK (Orissa - 47 million, Rajasthan - 83 million, UK - 68 million). If Bleepa fails to take off in the UK NHS this financial year then India must pick up the slack.

We have an Indian partner in QURE.AI and the Orissa pilot has 'recently (been) deployed at a pilot hospital' so I'm not unduly concerned about India.

As for the lack of trades recently, surely that shows we just have very few soft sellers about in the market place, and few buyers also as I suspect that they are awaiting news of signed contracts to limit buying risk. They appear to want financial security at the risk of paying a higher share price after contracts news breaks.

lr2
14/2/2022
14:09
The frustrating thing here is that it would only take a couple of CDC contracts to put Feedback into a very serious potential growth category.

The risk I’m worried about is that they don’t sell the basic system first as a starter and end up with lots of “extras” requested that need development.

That would be time for TO to put on a commercial hat. If the NHS are serious, put some money on the table and enter a development contract on top of the base system contract.

If a customer likes something, their bluff has to be called early on. “Buy this now and use it to help and we’ll upgrade add-ons”.

yump
14/2/2022
14:02
Why don’t you just stay in your conspiracy echo chamber and stick to FDBK.
yump
14/2/2022
13:21
Who was that poster who only takes his cue from the idiot Dr John Campbell when it comes to all matters relating to the jabs?
Well, the idiot now is suggesting the risk of developing myocarditis is some 133 greater in those who volunteered to take part in the great experiment.
The same Campbell who was urging his 2mill plus subscribers to roll up their sleeves without a second thought despite alarming data suggesting otherwise.

petekand
14/2/2022
13:12
In all honesty you do suggest this every year and so you may be right one year.
Looking at the non-action in the trades column, I suspect the market does not seem to agree.
I note from results that Bleepa is now in the hands of circa 900 clinicians at Pennine. Feedback may as well change its status to that of a registered charity.
As far as the latest interview is concerned, Tom sounds a little uncertain in my opinion, banging on about the AWS grant and at the same time stating we need Indian partners to begin the pilot. There is absolutely nothing new except the same waffle he has been repeating for the last two years.

petekand
14/2/2022
07:24
My thought too.
ducatiman
14/2/2022
06:51
I suspect we'll have lots of news in March and April.
lr2
14/2/2022
05:02
Cheers LR2. Not long now, hopefully.
ducatiman
13/2/2022
20:55
Courtesy of Investor Bill over on the other place.
lr2
12/2/2022
16:32
Busy week indeed Ged.
Yep, next few months will tell.
Plenty of irons in plenty of fires!

ducatiman
12/2/2022
09:45
Ducatiman thanks. Post 9622, also in the header. Busy week?

Indeed Yump. It's going to be an interesting couple of months. Make or break time?

ged5
12/2/2022
09:37
9 CDC’s should yield something and give a clue to the future. At least that number is specific.
yump
12/2/2022
08:25
I don’t think this has been posted. Apologies if it has.
ducatiman
10/2/2022
22:21
"MPD also provides expertise and guidance in introducing new technologies and applications such as Bleepa to facilitate the safe
capture and sharing of images taken by clinical staff, including establishing protocols for patient consent, etc."
________________________________________

Full steam ahead at the Royal Berkshire NHS Foundation Trust then.

lr2
10/2/2022
16:40
Just going to mention that. I don't recall that being in the RNS.

Also page 23 breaks down the target markets.

ged5
10/2/2022
16:30
We are currently in discussion with ~9 CDCs
ragnarr
10/2/2022
16:13
1bond

I'm afraid what gets to me is that 3 of us made roughly that in the first year from an very early website until Google trashed it. That was literally from a bedroom (well 3 bedrooms).

Should have floated it.

yump
10/2/2022
16:03
Interim results presentationfor the 6 months ended 30 November 202110 February 2022https://fbkmed.com/wp-content/uploads/2022/02/FBK-Interim-Results-Investor-Presentation-10.02.22_website-version.pdf
ragnarr
10/2/2022
14:19
Its never good when a company has to resort to desperate sensational highlights to try and boost the share price and treat shareholders like fools. For example, Significant increase in revenues - reflecting initial Bleepa sales and highlighting strength of the Company's refocused business model. Revenues were up a minuscule 9% to £179k.

Whats the costs base,

When are you going to sign a meaningful contract delivering real revenues?

You have raised over £15m in the last two years and delivered zero!!!!

Promises, promises, promises

1bond
10/2/2022
12:25
Photon
;-))
Perhaps we still have the known unknowns and all that to come...

I just hope they don’t go crazy with spending before the first couple of decent contracts that demonstrate viability and scalability.

yump
Chat Pages: Latest  532  531  530  529  528  527  526  525  524  523  522  521  Older

Your Recent History

Delayed Upgrade Clock